PFE

The company's long history is a record of reinvention. Its first commercial product was a palatable form of a treatment for intestinal worms, and the founders built early success in fine chemicals. Pfizer supplied medicines such as tartaric acid and cream of tartar to the Union Army during the Civil War, became a leading producer of citric acid in the early twentieth century as demand for soft drinks grew, and then mastered deep-tank fermentation during the Second World War, which let it manufacture penicillin at scale for Allied troops. That fermentation expertise carried it into antibiotics and made it a major drug company in the postwar decades. The modern Pfizer, however, was assembled largely through enormous acquisitions. It bought Warner-Lambert in 2000 to take full control of the cholesterol drug Lipitor, which became the best selling medicine in history, then acquired Pharmacia in 2003 and Wyeth in 2009. Each deal added scale and products but also set up the recurring problem that has shaped the company for a generation, which is what to do when a giant, patent-protected drug eventually loses its exclusivity and cheaper copies flood in.

What Pfizer sells today spans several therapeutic areas. Vaccines remain a cornerstone, anchored by the Prevnar family of pneumococcal vaccines, one of the company's largest and most durable products, alongside the Comirnaty COVID-19 vaccine. Internal medicine includes the heart drug Eliquis, an anticoagulant that Pfizer markets in partnership with Bristol Myers Squibb and which has been among its biggest revenue sources, and Vyndaqel, a treatment for a rare and serious heart condition. Oncology has become the centerpiece of the company's growth plan, with established drugs such as the breast cancer treatment Ibrance and the prostate cancer drug Xtandi joined by a deep pipeline of newer cancer medicines. The company also sells antivirals, including the COVID-19 treatment Paxlovid, and a range of anti-infectives, inflammation treatments, and rare-disease therapies. Pfizer employs roughly 75,000 people and invests on the order of ten billion dollars a year in research and development.

The COVID-19 era is essential to understanding the company's current position. In 2020 and 2021 the Comirnaty vaccine and later the Paxlovid antiviral generated revenue at a scale almost no pharmaceutical product had ever reached, pushing Pfizer's total annual revenue to roughly one hundred billion dollars at the peak in 2022. That surge was always going to fade as governments stopped buying doses in bulk and the world shifted from emergency stockpiling to ordinary commercial demand. The decline was steep. Sales of the two COVID products fell dramatically as the company moved to selling on the open market, and Pfizer's total revenue dropped by tens of billions of dollars within a couple of years. The episode left the company with two opposite legacies. It generated an extraordinary pile of cash that funded a deal-making spree, and it created a difficult comparison problem, because the years after 2022 looked like decline even though the underlying non-COVID business kept growing. Management has spent considerable effort reminding investors that the base business, stripped of the pandemic products, grew in the years that followed. The episode also damaged the company's credibility on forecasting, because the scale of the pandemic demand was so far outside historical norms that estimating how quickly it would fade proved genuinely hard, and Pfizer repeatedly cut its guidance as the COVID products came down faster than expected. The lasting investor lesson was that a one-time event, however large, does not change the underlying durability of a drug portfolio, and that durability is what the years after the windfall have been about.

The largest single use of that cash was the acquisition of Seagen, a biotechnology company specializing in antibody-drug conjugates, which Pfizer agreed to buy in March 2023 for about 43 billion dollars and completed that December. Antibody-drug conjugates link a cancer-killing molecule to an antibody designed to home in on tumor cells, with the goal of delivering the toxic payload directly to the cancer while sparing healthy tissue. The technology is one of the most active areas in oncology, and Seagen brought approved products and a development pipeline that significantly expanded Pfizer's cancer franchise. The deal made oncology the company's stated top priority and a centerpiece of its plan to roughly double the number of cancer medicines it offers and to shift its mix toward biologics. Whether Seagen ultimately justifies its price depends on how its pipeline matures over the rest of the decade, but the acquisition clearly reoriented the company around cancer treatment.

Obesity has been a far more frustrating pursuit. The market for GLP-1 weight-loss drugs, dominated by Novo Nordisk and Eli Lilly, became one of the most valuable opportunities in the industry, and Pfizer has repeatedly tried and failed to develop a competitive oral entrant. The company abandoned one version of its experimental pill danuglipron in late 2023 after a high share of patients in a trial stopped taking it, then discontinued danuglipron entirely in April 2025 after a case of possible liver injury in a study participant. Those setbacks left Pfizer on the outside of a market it badly wanted to enter, so it changed tactics and bought its way in. In late 2025 Pfizer acquired Metsera, an obesity-drug developer, after a contentious bidding war with Novo Nordisk that pushed the value to around 10 billion dollars and ended only after the bid escalated and a competing offer drew antitrust scrutiny. The Metsera deal gives Pfizer a clinical-stage obesity portfolio, but it enters the field years behind the leaders and against rivals with approved products and oral pills of their own moving toward launch.

The defining financial challenge of the late 2020s is a patent cliff. A cluster of Pfizer's most important drugs loses exclusivity in a concentrated window, with Eliquis facing the end of its protection in the United States around 2028, the cancer drug Ibrance reaching a key patent expiration around 2027, and Xtandi and several other products following in the same period. By the company's own framing, products facing these losses represent a large share of revenue, and management has spoken of losing roughly seventeen to eighteen billion dollars in annual sales as the cliff plays out. This is the central reason for the urgency behind the Seagen acquisition, the obesity push, and a multibillion-dollar cost-cutting program meant to protect profitability while the company replaces the lost revenue. The bet is that new oncology launches, the acquired pipelines, and continued vaccine demand can fill the hole before the old drugs run off.

Competition is intense across every area Pfizer operates in. In oncology it faces Merck, whose immunotherapy Keytruda is the best selling drug in the world, along with AstraZeneca, Bristol Myers Squibb, and a crowded field of biotech developers chasing antibody-drug conjugates and other novel approaches. In vaccines its main pneumococcal competitor is Merck, while the COVID vaccine market it shares with Moderna has shrunk to a fraction of its pandemic size. In obesity it is the clear laggard behind Eli Lilly and Novo Nordisk. The broader pharmaceutical industry also operates under persistent pressure from drug-pricing politics in the United States, including provisions that allow the government to negotiate prices on certain high-spending medicines, a policy that touches several of Pfizer's largest products. The company's scale, its manufacturing depth, its global commercial reach, and its balance sheet remain genuine advantages, but none of them insulate it from the basic biology of patents expiring and pipelines having to deliver.

Leadership rests with Albert Bourla, a veterinarian by training who joined Pfizer in the 1990s, rose through its animal health and commercial operations, and became chief executive in 2019 and chairman the following year. Bourla led the company through the COVID vaccine effort, which cemented his public profile, and has since steered the aggressive acquisition strategy aimed at the patent cliff. The senior team includes chief financial officer David Denton and a leadership group organized around the company's main commercial and scientific divisions. The board was reelected at the 2026 annual meeting. The defining feature of how Pfizer is run in this period is a willingness to spend the pandemic windfall on large external deals rather than relying on internal research alone, a choice that places enormous weight on the company's ability to integrate acquisitions and turn purchased pipelines into approved products.

The forward question for an investor is whether Pfizer can execute its way across the patent cliff faster than that cliff erodes its revenue. The company has the cash, the scale, and a clear strategy, having concentrated its bets on oncology through Seagen and bought a late entry into obesity through Metsera. The risk is that both bets are expensive, neither is guaranteed, and the company is racing a clock set by the calendar of patent expirations it cannot move. Pipeline execution is the variable that matters most, because acquisitions only pay off if the acquired science reaches the market, and Pfizer's own history with internally developed obesity drugs is a reminder of how often promising candidates fail late. Set against that uncertainty is a durable core of vaccines and established medicines, a research operation with real depth, and a balance sheet large enough to absorb mistakes. The company that emerges on the other side of the late 2020s will look meaningfully different from the one the pandemic briefly made into a giant, and the shape of that company depends almost entirely on how many of today's bets actually work.